LA NEWSLETTER · GRATUITE
L'essentiel de l'actualité, passé au crible par les cinq plumes du Courrier. Dans votre boîte, chaque jour ouvré.
Gratuit. Vous restez libre de partir quand vous voulez.
JE M'INSCRIS lecourrierdesstrateges.frDans un établissement voué à l’innovation médicale, la recherche ne devrait jamais devenir une justification à l’effacement des patients. Or, à Strasbourg, les circonstances de l’annulation de dizaines d’examens destinés à des malades du cancer soulèvent une question élémentaire : qui doit répondre lorsque l’organisation d’un service hospitalier empêche l’accès aux soins ?
ABONNEMENT
Deux grands formats par jour. Les cinq plumes du Courrier. La série Sécession, le dimanche.
Le monde commente. Vous, vous comprenez.
S'ABONNER lecourrierdesstrateges.frSelon les conclusions du rapport définitif de l’Inspection générale des affaires sociales (Igas) et de l’Inspection générale de l’éducation, du sport et de la recherche (Igesr), remises en décembre 2025, l’Institut hospitalo-universitaire de Strasbourg présentait « de nombreuses irrégularités dans l’organisation de l’établissement ».
Les faits remontent à mars 2025. Un courriel interne daté du 14 mars demandait l’annulation de tous les scanners prévus ce jour-là, faute de manipulateurs disponibles. Quarante-trois patients ont été concernés, les professionnels étant mobilisés sur des recherches menées sur des cochons pour le compte d’entreprises privées.
Le 12 octobre 2026, Gabriel Weisser, proche d’un patient atteint d’un cancer, a saisi le procureur de la République de Strasbourg d’une plainte contre X pour « mise en danger de la vie d’autrui et omission de porter secours ». Il s’agit d’une plainte, et non d’une condamnation : la justice devra déterminer les responsabilités éventuelles.
TELEGRAM · L'INFO EN CONTINU
La newsletter vous donne le matin. Le fil vous donne l'instant.
Gratuit, et en continu.
REJOINDRE LE FIL t.me/resterlibreLe professeur Christian Debry, directeur de l’IHU, conteste l’idée d’un arbitrage entre recherche et soins. Il a notamment invoqué un risque d’absentéisme parmi les manipulateurs. Mais l’équipe d’imagerie serait passée de quatorze personnes à seulement trois ou quatre, une évolution qui pose la question des moyens humains et de la capacité de l’établissement à assurer ses missions.
Un autre élément interpelle : dans un courriel du 10 juin 2025, la direction rappelait au personnel son devoir de confidentialité et évoquait un licenciement en cas de prise de parole dans la presse. Cette consigne, rapportée dans le dossier, nourrit les interrogations sur la liberté d’alerte au sein de l’établissement.
TIPS · SANS ABONNEMENT
Un média libre vit de ses lecteurs. Un pourboire ponctuel, sans compte ni engagement, quand le cœur vous en dit.
Vous donnez ce que vous voulez. Vous restez libre.
LAISSER UN POURBOIRE merci !Cette affaire montre ce que devient un hôpital public lorsque la recherche contractuelle, rémunératrice, côtoie des soins en sous-effectif : la tentation de sacrifier le malade, qui ne rapporte rien à l’heure, à l’industriel, qui paye. Nénamoins,pour l'heure rien ne prouve encore que ce fut le cas ; c’est précisément ce que l’enquête devra établir. Dans un système où l’État est à la fois financeur, régulateur et juge de ses propres établissements, ce sont les citoyens qui doivent s’improviser.
Si vous voulez voir les vidéos exclusives de décryptage, rejoignez notre chaîne Telegram gratuite en cliquant sur ce lien :
Worshippers are attending mass and praying for Pope Leo XIV's recovery after doctors removed cancerous tissue on 13 October. The 71-year-old pontiff was diagnosed with lung cancer before undergoing an operation. The Vatican has reported his recovery is progressing as expected and the pope has thanked well-wishers for their prayers
Continue reading...
© Photograph: AP
© Photograph: AP
© Photograph: AP
by Fabio Giusepep Carlo Carisio
On October 13, 2020, two Chinese institutions (the School of Medicine at Zhejiang University, Hangzhou; the Life Sciences Institute and Innovation Center for Cell Signaling Network at Soochow University, Suzhou; and Anhui Anlong Gene Technology Co., Ltd., Hefei) published a study warning the world about the risks associated with mRNA and mDNA COVID-19 vaccines.
Their research highlighted the extremely high risk of severe autoimmune lung conditions.
Gospa News was among the very first outlets worldwide to report on this in February 2021—just weeks after the market launch of the Pfizer gene-based serum, which is now under investigation in the USA for concealed adverse effects.
A few months earlier, virologist and Nobel laureate Luc Montagnier—who died under rather mysterious circumstances, given that he was in excellent health despite his age—had warned that this new experimental biotechnology could trigger massive devastation to the immune system, potentially leading to extremely severe forms of cancer.
Over the past two years, the phenomenon of “turbo-cancer” linked to COVID vaccines has entered scientific literature, supported by dozens of studies as well as unequivocal results from medical tests and autopsies.
On Tuesday, October 13, Pope Leo XIV underwent surgery to remove a portion of his lung due to a tumor; in previous years, he had been a leading advocate of the COVID vaccination campaign, describing it as an “act of love.” Relying on information disseminated by the medical establishment, the then-bishop did not hesitate to spread the falsehood that mRNA Covid gene serums could limit transmission, a claim refuted from all quarters, most recently by the Florida Attorney General’s lawsuit against Pfizer, and previously by the authoritative journal *Science*.
These are facts, not opinions.
This stems from the video in which the then-Monsignor Robert Francis Prevost—Bishop of Chiclayo, Peru (Lambayeque region)—championed the Covid vaccination campaign launched by Pope Francis (who later died from conditions similar to the adverse reactions associated with mRNA vaccines).
Is there a faint possibility that, following his serious illness, a Christian like the current Pontiff—innately inclined to acknowledge and repent of his errors—might be ready to question the dangerous “Vaccine God” narrative?
This narrative was upheld by the Vatican to avoid defying the New World Order—comprising friends and profiteers of Big Pharma—during the SARS-CoV pandemic, a virus treacherously engineered in a laboratory.
If, as the Gospel states, Jesus Christ is the “way, the truth, and the life” (John 14:6), how do the Pope and the cardinals have the audacity to refrain from questioning the science to which they bowed?
That science did not arrive as a “gift of the Holy Spirit,” but rather as a business venture for the Big Pharma manufacturers of mRNA gene serums and for the sordid rulers—past and present—who continue to support these projects at the Siena Biotecnopolo, funded by the Meloni government.
Unfortunately for him, the Pope had to experience firsthand a highly probable adverse reaction to the very vaccines he had so imprudently and brazenly promoted
There is no proof of a correlation, nor will there ever be one; this is because the Vatican State—which was among the first in the world to mandate vaccination for its “subjects”—can never admit to an error of false “faith” so massive that it caused irreparable harm.
Yet, the health updates regarding Pope Leo XIV’s medical conditions echo with a sense of terrible nemesis, as they evoke two pathologies long listed among the most serious side effects of mRNA gene therapies:
Having made this long and inevitable preamble, let us look at what the Holy See’s official bulletin reports regarding the health issue facing the Bishop of Rome, Robert Francis Prevost.
“In a procedure lasting approximately 90 minutes—which was successful and free of complications, Pope Leo XIV had the lower lobe of his right lung removed; an intraoperative histological examination confirmed a diagnosis of pulmonary adenocarcinoma. The anticipated medical bulletin containing news on Pope Leo’s health arrived in the evening at 9:53 PM (Occtober, 13), just over two hours after the surgery performed this afternoon, October 13, at the Gemelli Policlinic,” writes Vatican News.
“In the bulletin released by the Holy See Press Office, Dr. Luigi Carbone—Director of the Directorate of Health and Hygiene for Vatican City State—and Professor Margaritora announced: ‘This afternoon, the Holy Father underwent the scheduled thoracic surgery. To ensure a radical resection, the lower lobe of the right lung was removed using a video-assisted technique. An intraoperative histological examination confirmed the diagnosis of pulmonary adenocarcinoma, as had been suspected based on pre-operative tests,'” the Vatican news site adds.
FREEMASONRY & VATICAN – 3. Pope XIV Magnifies the MASON FILMMAKER who Exalted the KU-KLUX KLAN
“The Holy Father,” the statement continues, “was in the operating room for approximately three hours; the surgery itself lasted about 90 minutes. The procedure was successful, and there were no complications.”
Following the surgery, Leo XIV “woke up normally and, after a brief period of observation, returned to his room on the tenth floor.”
Fabio Giuseppe Carlo Carisio – Founder and Director of Gospa News
RELATED POSTS
Esse sistema coleta e redireciona para o sistema circulatório um líquido claro, chamado linfa, que contém células de defesa, os linfócitos, que exercem um papel vital no sistema imunológico e na proteção contra infecções.
Quando os linfócitos que se acumulam são do tipo B, caracteriza-se um linfoma não Hodgkin como o diagnosticado no cantor Netinho e em 85% dos casos da doença. Há ainda os linfomas de células T (ou de linfócitos T) e os linfomas de células NK (células natural killer ou exterminadoras naturais), que são menos comuns.
A hematologista do Hospital A.C. Camargo Cancer Center Talita Maira Bueno da Silveira explica que, no caso específico do cantor, o linfoma não Hodgkin, apesar de ser do tipo B, era bem raro, por se caracterizar como um linfoma plasmoblástico, mais comum em pacientes imunossuprimidos.
“É um tipo específico desse linfoma, mais agressivo e mais difícil de tratar. A chance de cura desse linfoma é uma chance menor do que alguns outros linfomas não Hodgkin mais conhecidos”, explicou a hematologista.
De acordo com estimativas do Instituto Nacional de Câncer (Inca), 10.180 novos casos de linfomas não Hodgkin devem ser diagnosticados no país este ano, sendo 5.370 em homens e 4.810 em mulheres.
Os sintomas incluem gânglios aumentados, febre, suores noturnos intensos, perda de peso inexplicável e fadiga, variando conforme o subtipo e o ritmo de crescimento.
Também podem aparecer erupção cutânea avermelhada, disseminada pelo corpo, náusea, vômitos ou dor abdominal, coceira, tosse, dor de cabeça e dificuldade de concentração.
“As formas mais agressivas dos linfomas não Hodgkin podem ter estes e outros sintomas, que incluem dor no pescoço, nos braços ou no abdome, dificuldade para respirar, fraqueza nos braços ou nas pernas e em ambos, confusão mental”, destaca o AC Camargo Cancer Center.
Embora os pesquisadores ainda não saibam exatamente o que causa esse tipo de linfoma, alguns fatores de risco estão associados à doença, como idade, sexo, imunossupressão, doenças autoimunes, radiação e substâncias tóxicas.
A lista de fatores de risco inclui ainda a exposição a infecções virais e bacterianas, como o vírus de Epstein-Barr, o HIV, o HTLV (vírus linfotrópico da célula humana) e a bactéria Helicobacter pylori.
O diagnóstico é feito por meio de exames, como biópsia de linfonodos, punção de medula, raio-X, tomografia, ressonância magnética e PET-CT.
Também é feito o estadiamento, um processo que visa a definir a extensão do linfoma e se ele afetou outros órgãos. É por meio desse exame que se define o estágio do linfoma, cuja classificação vai de I a IV.
A letra E, de extensão é acrescentada se o linfoma é encontrado em órgão fora do sistema linfático, e a letra S indica que a doença alcançou o baço.
No estágio I, o linfoma é encontrado em apenas uma área de um gânglio linfático ou órgão do sistema linfático ou fora do sistema.
Quando o estágio é o II, há presença em dois ou mais grupos de gânglios linfáticos do mesmo lado do diafragma.
No estágio III, o linfoma está nas áreas de gânglios linfáticos acima e abaixo do diafragma.
Já no estágio IV, a doença se disseminou para um órgão que não pertence ao sistema linfático e não está perto do gânglio linfático.
O tratamento depende do estágio, sintomas e estado geral do paciente, mas é comum o uso de quimioterapia, radioterapia e, em casos específicos, anticorpos monoclonais, terapia-alvo com a imunoterapia e transplante de células-tronco.
A hematologista ressalta que, nos últimos anos, foram vistos muitos avanços no tratamento dos linfomas não Hodgkin, principalmente do tipo B, com a incorporação de novas estratégias, com drogas mais dirigidas para células tumorais e terapia celular.
“Essa é uma nova modalidade de tratamento que não ataca diretamente o tumor, e, sim, reativa o sistema imunológico para que ele ataque o tumor”, afirmou.
Atualmente, há duas modalidades de tratamento aprovadas para pacientes não curados com as terapias de primeira linha.
“Temos o biespecífico, que é uma medicação que o paciente recebe, que reativa o sistema imune. O outro é a CAR-T comercial, que não é produzida aqui no Brasil, mas que podemos fazer nesses pacientes que são portadores de linfoma do subtipo B”, finalizou.
Login